AstraZeneca announced promising cardiac results from a late-stage trial of a diabetes drug.
. The trial compared the effect of once-weekly Bydureon versus placebo, when added to usual type-2 diabetes care, dealt with the risk of various heart problems.
Elisabeth Björk, vice president, head of cardiovascular and metabolic diseases, global medicines development, AstraZeneca, said: “These top-line results from the EXSCEL trial provide robust evidence of the cardiovascular safety profile of Bydureon across a wide range of patients with type-2 diabetes. Furthermore, the trial design and broad inclusion criteria of EXSCEL offer physicians relevant data applicable to clinical practice.”
A full evaluation of the EXSCEL data is ongoing.
AstraZeneca employs about 1,500 in Delaware.
